SEC Form 3 · accession 0001104659-26-109399

Electra Therapeutics, Inc. · ETRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Table I — non-derivative securities

Table II — derivative securities

Explanation of responses

• F1Shares held directly by Westlake BioPartners Fund I, L.P. (Fund I). The general partner of Fund I is Westlake BioPartners GP I, LLC (GP I). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg (Seidenberg) is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
• F2Shares held directly by Westlake BioPartners Fund II, L.P. (Fund II). The general partner of Fund II is Westlake BioPartners GP II, LLC (GP II). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
• F3Shares acquired upon the automatic conversion of redeemable preferred stock on a 1:1 basis upon the closing of the Issuer's initial public offering without the payment of further consideration. Each Reporting Person had previously waived its right to voluntarily convert such redeemable preferred stock.